These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12858129)

  • 1. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
    Cottrell DA; Marshall BJ; Falko JM
    Curr Opin Cardiol; 2003 Jul; 18(4):301-8. PubMed ID: 12858129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of combination therapy for dyslipidemia: a lipid clinic approach.
    Brown AS
    Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for combined dyslipidemia.
    Xydakis AM; Ballantyne CM
    Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LDL reduction: how low should we go and is it safe?
    Robinson JG
    Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH).
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):471-477.e2. PubMed ID: 21392600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing diabetic dyslipidemia: beyond statin therapy.
    Neeli H; Gadi R; Rader DJ
    Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of fenofibrate with non-statin drug regimens.
    Agouridis AP; Filippatos TD; Derdemezis CS; Mikhailidis DP; Elisaf MS
    Curr Pharm Des; 2010 Oct; 16(30):3401-16. PubMed ID: 20819059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    Ayyobi AF; Brunzell JD
    Am J Cardiol; 2003 Aug; 92(4A):27J-33J. PubMed ID: 12957324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Falko JM; Moser RJ; Meis SB; Caulin-Glaser T
    Curr Diabetes Rev; 2005 May; 1(2):127-35. PubMed ID: 18220588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.
    Moon YS; Chun P; Chung S
    Drugs Today (Barc); 2007 Jan; 43(1):35-45. PubMed ID: 17315051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy for dyslipidemia: safety and regulatory considerations.
    Davidson MH
    Am J Cardiol; 2002 Nov; 90(10B):50K-60K. PubMed ID: 12467940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperlipidemia and fibrates with special reference to diabetes].
    Henkel E; Hanefeld M
    Herz; 2001 Dec; 26(8):523-30. PubMed ID: 11820155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.